-
Mashup Score: 0Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors: - 8 hour(s) ago
AbstractBackgroundHormone therapies, including aromatase inhibitors and tamoxifen, are used with ovarian suppression to improve outcomes in premenopausal patients with breast cancer. Cardiovascular…
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Transcatheter Tricuspid Valve Replacement With EVOQUE and Mitral Valve Repair With PASCAL in One Procedure: - 10 hour(s) ago
AbstractMitral and tricuspid regurgitation, linked to high morbidity and mortality, are increasingly treated with interventional edge-to-edge repair, showing excellent results in favorable anatomy….
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
New #JACCCaseReports clinical case presents an 80y/o female patient w/ severe dyspnea & marked leg edema. She was treated w/ diuretic agents in an outpatient clinic for several months but was now experiencing progressive symptoms. https://t.co/vgzogSF0QR #TTVR #EVOQUE #PASCAL https://t.co/HNkrYz9Yif
-
-
Mashup Score: 2Responder Analyses Can Be Misleading: - 11 hour(s) ago
∗Addr ess for correspondence: Dr Mary Ross Southworth, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Building 22, Silver Spring, Maryland 20993, USA. E-mail: E-mail Address: [email protected] Published by Elsevier on Behalf of The American College of Cardiology Foundation. Received September 20, 2024 Accepted November 7, 2024 Published online January 13,
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
Did the statistical analysis in FINEARTS-HF confuse the outcomes? 🤔 Get the details in #JACC: https://t.co/4iwOtwjm7N #FINEARTSHF #HeartFailure #HFpEF @mpsotka @JEPomeroyMDPhD https://t.co/QghgkkSyOH
-
-
Mashup Score: 0Call-for-Papers | JACC: Advances - 13 hour(s) ago
JACC: Advances is calling for papers for a special focus issue on
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
📢 #JACCAdvances is seeking papers for a special issue on "Care of the Critically Ill Patient in the Cardiac #ICU." Topics include outcomes, therapies, ethics, and health system strategies in #CriticalCare Cardiology. Learn more & submit today: https://t.co/vBylnHn4yz https://t.co/9ILGEVUed1
-
-
Mashup Score: 12Catheter Ablation for Ventricular Tachycardia in Patients With Biopsy-Proven Myocarditis: - 13 hour(s) ago
AbstractBackgroundCatheter ablation (CA) is increasingly recognized as an effective treatment for ventricular tachycardia (VT) in myocarditis patients, although current evidence is based on less ro…
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
In biopsy-proven #myocarditis pts, VT ablation ⬇️ #arrhythmia recurrences. Acute stage of myocarditis was associated with less favorable outcomes https://t.co/nF70e6rIGP Editorial comment by @MurataHiroshige: https://t.co/XOvJZUO01a #JACCAsia #Epeeps #ablateVT https://t.co/KIm9prO3e4
-
-
Mashup Score: 4A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial - 1 day(s) ago
AbstractBackgroundFirst-generation bioresorbable scaffolds (BRS) increased risks of stent thrombosis and adverse events. The Bioheart scaffold is a new poly-L-lactic acid–based BRS.ObjectivesThis s…
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
The #BIOHEART II #RCT demonstrated noninferiority of the Bioheart bioresorbable scaffolds compared to #DES for 1-yr in-segment late luminal loss and comparable #TLF at 3 yrs in-segment late loss, and resulted in a comparable 3-yr clinical outcome https://t.co/IbfaaW5ulg #JACCINT https://t.co/FwV6iW9P5D
-
-
Mashup Score: 2Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial - 1 day(s) ago
AbstractBackgroundPatients with heart failure (HF) and a recent worsening heart failure (WHF) event are known to be at high risk of recurrent hospitalization and death, regardless of ejection fract…
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
(7/13) Second, Dr. @akshaydesaimd of @BrighamWomens and colleagues found that patients with a recent event of worsening #heartfailure appeared to experience even greater clinical benefit from #finerenone https://t.co/UwZILsikaK #JACC https://t.co/pjM8vrA02H
-
-
Mashup Score: 5JACC | Priorities for Evidence Generation - 1 day(s) ago
In clinical practice, we frequently encounter critical questions for which we lack solid evidence. Whether on rounds or in the clinic, we often make decisions under uncertainty, wondering, “Why don’t we have data that answers this question?” To bridge these gaps, we at JACC are partnering with the FDA to surface these key questions. We want to hear directly from you: What pressing questions do you face regarding the use of FDA-regulated products—drugs, biologics, devices, food, and tobacco—that impact
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
#JACC & @US_FDA are collaborating to identify questions and barriers clinicians face with #FDA-related products affecting CV health. Your input will guide resource development to address these gaps. Submit comments here 👉 https://t.co/zNozOkpYJI @haiderwarraich @hmkyale… https://t.co/w1LuIAN0TM https://t.co/L1F2MmuskC
-
-
Mashup Score: 24Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations - 2 day(s) ago
AbstractThe administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced …
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
ICYMI: What to look out for in CV health during cancer therapy? Discover key aspects of cardioprotection, surveillance, permissive cardiotoxicity, and more. Insights from the #JACCCardioOnc expert panel: https://t.co/JXbVQWh4FU #CardioOnc @DarrylLeong @sdent_cardioonc @SWaliany… https://t.co/vrxtBDJknb https://t.co/s2nZxnYNXe
-
-
Mashup Score: 39
American College of Cardiology Representative. American College of Cardiology Representative. American College of Cardiology Representative. Heart Failure Society of America Representative. American College of Cardiology Representative. Heart Rhythm Society Representative. American College of Cardiology Representative. American College of Cardiology Representative. American College of Cardiology Representative. American College of Cardiology Representative. American College of Cardiology Representative.
Source: www.jacc.orgCategories: General Medicine News, Partners & KOLsTweet-
🆕 multisociety Appropriate Use Criteria published in #JACC focus on #CIEDs, specifically ICDs, CRT & pacing. The updated criteria address a broad spectrum of clinical scenarios & 🔑 areas where new data are available https://t.co/bUB4P2yQp9 #epICD #EPeeps @DesaiMilindY… https://t.co/RUcfEnsQTC https://t.co/RndL0EgYNR
-
Premenopausal #BreastCA survivors treated with aromatase inhibitors & ovarian suppression face a 2.2-fold higher risk of #CVD compared to those on #tamoxifen. Regular #CVhealth monitoring is crucial. More: https://t.co/8CW5dWZHfd #JACCCardioOnc #BCsm #CardioOnc @ElizPolter… https://t.co/u7neSsWPv8 https://t.co/TpE5TPg0i4